BioCentury
ARTICLE | Clinical News

Daxas roflumilast: Additional Phase III data

November 16, 2009 8:00 AM UTC

Additional data from the double-blind, international Phase III HELIOS trial in 743 patients showed that once-daily 500 ug oral Daxas plus Spiriva tiotropium for 24 weeks significantly improved breath...